newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

  • IGC Pharma added Visionary Investigators Network (VIN) as a clinical research site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease dementia.
  • The CALMA trial enrollment is approximately 70% complete.
  • VIN operates an integrated model embedding research within private neurology practices to support efficient enrollment & patient continuity.
  • The CALMA trial at VIN will be conducted at the Coconut Grove location in Miami, Florida, led by Principal Investigator Dr. Andrew Lerman.
  • The CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study assessing the safety & efficacy of the cannabinoid-based therapy IGC-AD1.
  • VIN specializes in neurodegenerative disorders & operates across South Florida with the Coconut Grove site selected for its specific research strengths.
  • IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer's & metabolic disorders.
  • IGC Pharma's pipeline includes IGC-AD1, TGR-63 targeting amyloid plaques, & early-stage programs focused on neurodegeneration, tau proteins, & metabolic dysfunctions.
  • The press release includes forward-looking statements regarding risks such as regulatory approval, commercialization success, & potential AI algorithm failures.